<DOC>
	<DOCNO>NCT00282828</DOCNO>
	<brief_summary>This study compare effectiveness either add clonazepam placebo standard treatment switch venlafaxine treat generalize social anxiety disorder individual respond treatment sertraline .</brief_summary>
	<brief_title>Improving Treatment Outcomes Pharmacotherapy Generalized Social Anxiety Disorder</brief_title>
	<detailed_description>Generalized social anxiety disorder ( GSAD ) one common psychiatric disorder , often cause significant distress dysfunction affect individual . Although currently available treatment GSAD effective , individual residual symptom initial psychosocial psychopharmacologic intervention . Further treatment necessary individual , sufficient research do guide clinician safest effective next step may . This study compare effectiveness either combine clonazepam placebo sertraline completely switch venlafaxine treat GSAD individual respond treatment sertraline . This study also examine predictor treatment response , include factor age disease onset , duration illness , comorbidities , gene influence serotonin catecholamine metabolism . Participants double-blind study first partake initial 10-week phase treat sertraline . Participants respond sertraline treatment proceed phase two study , randomly assign one three treatment group . One group receive sertraline clonazepam , another group receive sertraline placebo , third group receive venlafaxine . All treatment continue 12 week . Sertraline venlafaxine FDA-approved treatment GSAD . Clonazepam widely use treatment anxiety , FDA-approved treatment GSAD . All participant attend weekly study visit Weeks 1 , 2 , 4 , 6 , 8 , 10 . Participants continue phase two attend weekly study visit Weeks 11-14 , 16 , 18 , 20 , 22 . Symptom remission rate post-treatment social phobia severity assess Week 22 .</detailed_description>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<mesh_term>Clonazepam</mesh_term>
	<criteria>Primary psychiatric diagnosis GSAD define DSMIV criterion score 60 LSAS Agrees use effective form contraception throughout study Clinically significant abnormality find upon physical examination , electrocardiogram , laboratory test History two unsuccessful , adequate treatment trial , indicate lack response 10 week follow : SSRIs ( e.g. , 40 mg paroxetine equivalent per day ) ; benzodiazepine ( e.g . least 2.5 mg clonazepam per day ) plus antidepressant ( adequate dose ) ; monoamine oxidase inhibitor ( e.g. , 60 mg phenelzine equivalent per day ) ; single fail trial 10 week venlafaxine ( least 150 mg per day ) Pregnant breastfeed Simultaneous use psychotropic medication , exception psychostimulants treat ADHD ; participant must discontinue regular benzodiazepine antidepressant therapy least two week ( 5 week fluoxetine ) prior study entry ; betablockers must discontinue unless indicate medically ( e.g. , hypertension ) DSMIV diagnosis follow : lifetime history schizophrenia psychosis , mental retardation , organic medical disorder , bipolar disorder , obsessive compulsive disorder ; eat disorder past 6 month ; alcohol substance abuse past 3 month dependence within past 6 month ( entry participant major depression , dysthymia , panic disorder , generalize anxiety disorder , posttraumatic stress disorder permit social anxiety disorder judge predominant disorder ) Significant suicidal ideation indicate score great 3 MontgomeryAsberg Depression Rating Scale suicidal behavior within 6 month prior study entry Significant personality dysfunction could interfere study participation Serious medical illness instability hospitalization may likely study Seizure disorder , exception childhood history isolate , nonrecurrent febrile seizures Any concurrent psychotherapy initiate within 3 month study entry , ongoing psychotherapy duration direct specifically toward treatment GSAD ( prohibit psychotherapy include cognitive behavioral therapy psychodynamic therapy focus explore specific , dynamic cause phobic symptomatology provide management skill ; general supportive therapy 3 month acceptable )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Social Anxiety Disorder</keyword>
	<keyword>Pharmacotherapy</keyword>
	<keyword>Genetics</keyword>
	<keyword>Treatment Refractory</keyword>
</DOC>